We further analyzed CD62L expression on CT26-specific CD8+ T cells and found that CD62L−CT26-specific CD8+ T cells (ie, effector cells capable of infiltrating non-lymphoid peripheral tissues including the tumor) were the dominantly expanded population in mice treated with ICIs plus IL-2/JES6, with ∼12-times higher abundance of this population compared with control mice (online supplemental figure 8D and F). This evidence concerns the gene DDX53 and neoplasm.